Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

Revenue projections:

Revenue projections for PPLPHARMA
Revenue projections for PPLPHARMA

Revenues for PPLPHARMA are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 0.000000
forwardPE 56.655033
debtToEquity 60.533000
earningsGrowth -0.625000
revenueGrowth 0.125000
grossMargins 0.597880
operatingMargins 0.063940
trailingEps 0.340000
forwardEps 0.000000

PPLPHARMA's high forward PE ratio signals potential overvaluation, limiting further price gains and increasing the risk of a correction. This metric should be carefully considered alongside other key fundamentals to assess the stock's future performance.
Piramal Pharma Limited's low growth in both earnings and revenue signals a potential profit decline. This could be a sign of financial trouble, suggesting that the company's profitability might shrink in the near future.
PPLPHARMA's negative gross and operating margins suggest that the company is experiencing losses at both the production and operational levels. This could point to inefficiencies or declining demand for its products.

Price projections:

Price projections for PPLPHARMA
Price projections for PPLPHARMA



Recommendation changes over time:

Recommendations trend for PPLPHARMA
Recommendations trend for PPLPHARMA


Analysts' buy bias toward PPLPHARMA suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, PPLPHARMA is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.